Bluebird Bio is a clinical-stage biotechnology company that develops transformative gene therapies for severe genetic diseases and cancer. The Company's clinical programs in severe genetic diseases include LentiGlobin product candidate to treat transfusion dependent β-thalassemia and to treat severe sickle cell disease and itsLenti-D product candidate to treat cerebral adrenoleukodystrophy.
Type | Public | |
Founded | 1992 | |
HQ | Cambridge, MA, US | Map |
Website | bluebirdbio.com | |
Employee Ratings | More |
USD | |
---|---|
Revenue (FY, 2020) | 250.7m |
Gross profit (FY, 2020) | 245.3m |
Gross profit margin (FY, 2020), % | 97.8% |
Net income (FY, 2020) | (622.3m) |
EBIT (FY, 2020) | (623.0m) |
Market capitalization (25-Feb-2021) | 1.9b |
Closing stock price (25-Feb-2021) | 28.1 |
Cash (31-Dec-2020) | 317.7m |
EV | 1.8b |
USD | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 6.3m | 6.4m | 6.3m | 6.3m | 6.4m | 6.3m | 4.9m | 1.3m | 1.5m | 1.6m | 1.6m | 6.8m | 16.7m | 7.7m | 16.0m | 7.9m | 11.5m | 12.5m | 13.3m | 8.9m | 21.9m | 78.4m | 13.4m |
Cost of goods sold | 21.0k | 29.0k | 430.0k | 613.0k | 862.0k | 1.0m | |||||||||||||||||
Gross profit | 7.8m | 11.5m | 12.0m | 12.7m | 8.0m | 20.8m | |||||||||||||||||
Gross profit Margin, % | 100% | 100% | 97% | 95% | 90% | 95% |
USD | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 228.8m | 216.8m | 192.5m | 175.7m | 89.6m | 133.2m | 593.3m | 417.5m | 192.6m | 222.6m | 245.2m | 216.0m | 686.3m | 238.0m | 456.5m | 333.9m | 952.1m | 221.7m | 281.0m | 300.4m | 346.6m | 1.2b | 324.2m |
Prepaid Expenses | 1.7m | 4.7m | 2.7m | 4.1m | 4.8m | 4.0m | 4.5m | 5.0m | 7.9m | 7.1m | 7.9m | 8.7m | 15.0m | 13.9m | 28.3m | 24.1m | 24.1m | 23.8m | 25.4m | 26.9m | 40.2m | 39.4m | 35.4m |
Current Assets | 230.5m | 221.5m | 195.9m | 182.9m | 223.3m | 340.8m | 815.5m | 713.2m | 561.0m | 582.9m | 608.8m | 667.3m | 1.1b | 758.7m | 1.2b | 1.1b | 1.7b | 1.4b | 1.3b | 1.2b | 967.5m | 1.6b | 1.3b |
PP&E | 2.5m | 5.4m | 12.0m | 12.9m | 15.0m | 16.9m | 16.8m | 61.6m | 96.6m | 109.3m | 131.7m | 181.7m | 180.4m | 182.4m | 204.2m | 219.2m | 232.9m | 114.0m | 129.1m | 144.1m | 153.9m | 155.4m | 157.7m |
USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|
Net Income | (25.3m) | (48.7m) | (166.8m) | (263.5m) | (335.6m) | (555.6m) | (789.6m) | |
Depreciation and Amortization | 941.0k | 4.2m | 7.4m | 9.6m | 13.5m | 17.2m | 17.4m | 19.4m |
Accounts Payable | 2.1m | (2.2m) | 2.5m | 6.7m | 526.0k | 3.6m | 23.6m | (20.1m) |
Cash From Operating Activities | 43.5m | (59.7m) | (98.4m) | (189.6m) | (280.6m) | (413.4m) | (564.4m) | (470.4m) |
USD | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (11.1m) | (17.2m) | (10.6m) | (12.1m) | (29.2m) | (24.8m) | (76.6m) | (119.5m) | (56.3m) | (115.1m) | (192.1m) | (68.7m) | (139.6m) | (218.4m) | (115.1m) | (261.1m) | (406.6m) | (164.4m) | (360.2m) | (566.3m) | (202.6m) | (224.1m) | (418.8m) |
Depreciation and Amortization | 304.0k | 610.0k | 475.0k | 1.0m | 2.6m | 1.7m | 3.5m | 5.4m | 2.3m | 4.7m | 7.1m | 2.8m | 6.3m | 9.9m | 4.0m | 8.2m | 12.6m | 3.8m | 7.8m | 12.4m | 4.9m | 9.4m | 14.4m |
Accounts Payable | (1.4m) | (1.0m) | (2.4m) | (2.7m) | (2.6m) | (331.0k) | (418.0k) | 623.0k | (2.2m) | (3.1m) | 1.2m | (3.3m) | 2.0m | (447.0k) | (737.0k) | 4.1m | (493.0k) | 10.6m | 6.7m | 23.3m | (9.5m) | (14.0m) | (15.4m) |
Cash From Operating Activities | 57.8m | 48.9m | (11.9m) | (23.3m) | (44.0m) | (24.2m) | (36.3m) | (65.3m) | (36.8m) | (81.1m) | (120.5m) | (75.3m) | (128.8m) | (185.2m) | (108.8m) | (209.2m) | (283.7m) | (154.2m) | (292.0m) | (405.4m) | (206.1m) | (166.4m) | (315.2m) |
USD | Q2, 2013 |
---|---|
Financial Leverage | 1.5 x |
Bluebird Bio has 9.03k Twitter Followers. The number of followers has increased 2.4% month over month and increased 4% quarter over quarter
1.3k
Tweets
762
Following
9k
Followers
11
Tweets last 30 days
5.1
Avg. likes per Tweet
100%
Tweets with engagement
When was Bluebird Bio founded?
Bluebird Bio was founded in 1992.
Who are Bluebird Bio key executives?
Bluebird Bio's key executives are Derek Adams, Jenn Snyder and Jason F. Cole.
How many employees does Bluebird Bio have?
Bluebird Bio has 1,090 employees.
What is Bluebird Bio revenue?
Latest Bluebird Bio annual revenue is $250.7 m.
What is Bluebird Bio revenue per employee?
Latest Bluebird Bio revenue per employee is $230 k.
Who are Bluebird Bio competitors?
Competitors of Bluebird Bio include Genprex, Bellicum Pharmaceuticals and Modis Therapeutics.
Where is Bluebird Bio headquarters?
Bluebird Bio headquarters is located at 60 Binney St, Cambridge.
Where are Bluebird Bio offices?
Bluebird Bio has offices in Cambridge, Durham and Seattle.
How many offices does Bluebird Bio have?
Bluebird Bio has 3 offices.
Receive alerts for 300+ data fields across thousands of companies